Aclaris Therapeutics (ACRS) Payables (2014 - 2026)

Aclaris Therapeutics' Payables history runs 13 years deep, the most recent figure standing at $14.7 million for Q1 2026.

• In Q1 2026, Payables rose 131.84% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $14.7 million (up 131.84% YoY), while the FY2025 annual figure was $13.2 million, up 180.55% from the prior year.
• Payables was $14.7 million for Q1 2026 at Aclaris Therapeutics, up from $13.2 million in the prior quarter.
• In the past five years, Payables ranged from a high of $14.7 million in Q1 2026 to a low of $4.7 million in Q4 2024.
• Historically, Payables has averaged $9.0 million across 5 years, with a median of $8.8 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Payables plunged 47.17% in 2024, then surged 180.55% in 2025.
• A 5-year view of Payables shows it stood at $10.4 million in 2022, then declined by 14.23% to $8.9 million in 2023, then tumbled by 47.17% to $4.7 million in 2024, then soared by 180.55% to $13.2 million in 2025, then grew by 11.95% to $14.7 million in 2026.
• The last three Payables figures came in at $14.7 million (Q1 2026), $13.2 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.